Bionano Announces Effective Date of Reverse Stock Split

Core Viewpoint - Bionano Genomics, Inc. will implement a reverse stock split at a ratio of 1-for-60, effective January 24, 2025, with trading on a split-adjusted basis starting January 27, 2025 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every 60 shares of common stock into one share, maintaining the par value at $0.0001 per share [3]. - A new CUSIP number, 09075F404, will be assigned to the common stock effective January 27, 2025, while the stock will continue to be listed on the Nasdaq Capital Market under the symbol "BNGO" [3]. - The reverse stock split will proportionately reduce the number of shares issuable upon conversion of outstanding convertible debentures and the exercise of stock options, restricted stock units, and warrants [3]. Group 2: Impact on Shareholders - No fractional shares will be issued; instead, stockholders entitled to a fractional share will receive a cash payment [4]. - The reverse stock split will affect all common stockholders proportionally, not altering their percentage ownership except in cases of fractional shares [4]. - Stockholders holding shares through banks or brokers will have their positions automatically adjusted without needing further action [5]. Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications through optical genome mapping (OGM) [7]. - The company offers a range of products including OGM solutions, diagnostic services, and software, with a focus on transforming genomic analysis [7].